Literature DB >> 9848433

Is prophylactic treatment after myocardial infarction evidence-based?

C Brotons1, F Calvo, P Cascant, A Ribera, I Moral, G Permanyer-Miralda.   

Abstract

OBJECTIVE: We aimed to evaluate the use of evidence-based prophylactic treatment after myocardial infarction on hospital discharge and in primary care after 1 year of hospitalization. METHODS AND
RESULTS: We conducted a 1-year prospective study of all the patients discharged from a tertiary hospital who had been treated for myocardial infarction from January 1 to December 31 1995. Three hundred and eighty surviving patients were consecutively discharged from the hospital. Seventy per cent of patients were treated with aspirin, 45% with beta-blockers, 27% with calcium channel blockers, 26% with ACE inhibitors, 40% with nitrates and 8% with cholesterol-lowering drugs after discharge from the hospital. In primary care, prescription of lipid-lowering drugs increased to 17%, while prescription of beta-blockers decreased to 34%. ACE inhibitor prescriptions at discharge were clearly more common in patients with impaired ventricular function or heart failure (57%).
CONCLUSION: According to the evidence, there is still potential for reducing the risk of a further ischaemic event or death in patients with MI, especially by increasing the use of beta-blockers and lipid-lowering drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9848433     DOI: 10.1093/fampra/15.5.457

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  2 in total

1.  [The secondary prevention of ischaemic heart disease in Spain. A systematic review of observational studies].

Authors:  Gabriel Sanfélix; Salvador Peiró; Victoria Gosalbes Soler; Pedro Cervera Casino
Journal:  Aten Primaria       Date:  2006-09-30       Impact factor: 1.137

2.  Medication Management Among Medicaid Myocardial Infarction Survivors.

Authors:  Erica B Oberg; Annette L Fitzpatrick; William E Lafferty; James P Logerfo
Journal:  Wash State J Public Health Pract       Date:  2008-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.